Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

PHASE2UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 2, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AZD9291

AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state

Trial Locations (13)

26504

University Hospital of Patra-Rio, Rio

71110

University Hospital of Heraklion Crete, Heraklion

Unknown

251 Air Forces Military Hospital of Athens, Athens

"Anticancer Hospital of Athens Agios Savvas", Athens

"Athens Hospital Mitera Hygia Polis", Athens

"General Hospital of Athens Aretaieio", Athens

"General Hospital of Athens Evangelismos", Athens

"General Oncology Hospital of Athens Ag. Anargiroi", Athens

IASO General Hospital, Athens

"Universtiy Hospital of Athens Attikon", Athens

Diabalkaniko General Hospital of Thessaloniki, Thessaloniki

"General Hospital of Thesaloniki G. Papanikolaou", Thessaloniki

Thessaloniki Bioclinic, Thessaloniki

All Listed Sponsors
lead

Hellenic Oncology Research Group

OTHER